CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2
| العنوان: | CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2 |
|---|---|
| المؤلفون: | Angele Breithaupt, Björn Corleis, Stefan O. Mueller, Martin Beer, Bernd Hoffmann, Claudia Wylezich, Franziska Sick, Nico Joel Halwe, Nicole Roth, Janine Mühe, Lorenz Ulrich, Moritz Thran, Benjamin Petsch, Donata Hoffmann, Jacob Schön, Anca Dorhoi, Anna Michelitsch, Kerstin Wernike, Andreas Thess, Anna Kraft, Charlie Fricke, Susanne Rauch, Thomas C. Mettenleiter |
| المصدر: | Nature Communications Nature Communications, Vol 12, Iss 1, Pp 1-7 (2021) |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | 0301 basic medicine, Genetically modified mouse, COVID-19 Vaccines, Science, General Physics and Astronomy, Mice, Transgenic, Genome, Viral, Antibodies, Viral, General Biochemistry, Genetics and Molecular Biology, Neutralization, Article, Cell Line, 03 medical and health sciences, Mice, 0302 clinical medicine, Chlorocebus aethiops, Animals, Humans, Neutralizing antibody, Vero Cells, Messenger RNA, Vaccines, Multidisciplinary, biology, SARS-CoV-2, COVID-19, General Chemistry, Virology, Antibodies, Neutralizing, Titer, 030104 developmental biology, Cell culture, 030220 oncology & carcinogenesis, Spike Glycoprotein, Coronavirus, biology.protein, Vero cell, Angiotensin-Converting Enzyme 2, Antibody |
| الوصف: | The ongoing SARS-CoV-2 pandemic necessitates the fast development of vaccines. Recently, viral mutants termed variants of concern (VOC) which may escape host immunity have emerged. The efficacy of spike encoding mRNA vaccines (CVnCoV and CV2CoV) against the ancestral strain and the VOC B.1.351 was tested in a K18-hACE2 transgenic mouse model. Naive mice and mice immunized with a formalin-inactivated SARS-CoV-2 preparation were used as controls. mRNA-immunized mice develop elevated SARS-CoV-2 RBD-specific antibody and neutralization titers which are readily detectable, but significantly reduced against VOC B.1.351. The mRNA vaccines fully protect from disease and mortality caused by either viral strain. SARS-CoV-2 remains undetected in swabs, lung, or brain in these groups. Despite lower neutralizing antibody titers compared to the ancestral strain BavPat1, CVnCoV and CV2CoV show complete disease protection against the novel VOC B.1.351 in our studies. Emerging SARS-CoV-2 variants with mutations in the spike protein raise concerns regarding vaccine efficacy. Here, the authors show that two spike encoding mRNA vaccines in preclinical and clinical development protect human ACE2 mice from the B.1.351 variant of concern and ancestral B BavPat1. |
| تدمد: | 2041-1723 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e07cdb994baccdba4d8371fe5a99921 https://pubmed.ncbi.nlm.nih.gov/34193869 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....7e07cdb994baccdba4d8371fe5a99921 |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 20411723 |
|---|